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Abstract
Immune surveillance system can detect more efficiently secretory tumor-specific antigens, which are superior as a target for
cancer immunotherapy. On the contrary, immune tolerance can be induced in the thymus when a tumor antigen is
massively secreted into circulation. Thus, the secretion of tumor-specific antigen may have contradictory roles in tumor
immunity in a context-dependent manner. However, it remains elusive on the precise cellular mechanism of intrathymic
immune tolerance against tumor antigens. We previously demonstrated that a minor thymic conventional dendritic cell
(cDC) subset, CD8a2Sirpa+ cDCs, but not the major subset, CD8a+Sirpa2 cDCs can selectively capture blood-borne antigens
and crucially contribute to the self-tolerance. In the present study, we further demonstrated that Sirpa+ cDCs can capture a
blood-borne antigen leaking inside the interlobular vascular-rich regions (IVRs). Blood-borne antigen selectively captured by
Sirpa+ cDCs can induce antigen-specific Treg generation or negative selection, depending on the immunogenicity of the
presented antigen. Furthermore, CCR2 expression by thymic Sirpa+ cDCs and abundant expression of its ligands,
particularly, CCL2 by tumor-bearing mice prompted us to examine the function of thymic Sirpa+ cDCs in tumor-bearing
mice. Interestingly, tumor-bearing mice deposited CCL2 inside IVRs in the thymus. Moreover, tumor formation induced the
accumulation of Sirpa+ cDCs in IVRs under the control of CCR2-CCL2 axis and enhanced their capacity to take up antigens,
resulting in the shift from Treg differentiation to negative selection. Finally, intrathymic negative selection similarly ensued
in CCR2-competent mice once the tumor-specific antigen was secreted into bloodstream. Thus, we demonstrated that
thymic Sirpa+ cDCs crucially contribute to this novel process of intrathymic tumor immune tolerance.
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Introduction
Immune surveillance system can detect more efficiently
secretory tumor-specific antigens than intracellular ones. Thus, it
is widely believed that secretory antigens are superior as a target
for cancer immunotherapy to intracellular antigens [1,2]. On the
contrary, immune tolerance can be induced when a tumor antigen
is massively secreted into circulation. Supporting the latter notion,
tumor antigen-specific CD4+ T cells were eliminated in the
thymus and draining lymph nodes in the mice bearing a tumor,
which constitutively secreted an antigen into the circulation [3,4].
Thus, a secretory tumor antigen may have contradictory roles in
tumor immunity in a context-dependent manner. However, it
remains elusive on the precise cellular mechanism and molecular
regulation of immune tolerance against secretory tumor antigens.
Intrathymic educational processes consist of the induction of
negative selection and natural Treg differentiation, and participate
in orchestrating central immune tolerance, thereby reducing the
risk of developing autoimmune disorders. Negative selection, a
cardinal recessive tolerance process, is crucial for the maintenance
of immune homeostasis while Treg-mediated immune regulation
is a main gateway to dominant tolerance and can intervene in
ongoing abnormal immune responses. Central tolerance is
accurately executed by several antigen presenting cells (APCs)
including medullary thymic epithelial cells (mTECs) and thymic
DCs. A transcription factor, autoimmune regulator (AIRE) [5], is
selectively expressed in mTECs and to a lower extent, thymic
DCs, and constitutively regulates the transcription of tissue-
restricted antigens in mTECs, thereby inducing central tolerance,
negative selection and Treg differentiation from thymocytes which
can recognize the antigens expressed in mTECs [5,6,7,8,9].
Additionally, some DCs can convey the peripheral self-antigens to
the thymus, resulting in the induction of negative selection and
Treg differentiation in the DC-dependent manner [10,11].
Recently, Wu and Shortman classified thymic DCs into three
subsets, CD11c+CD11b2CD8a+Sirpa2 and
CD11c+CD11b+CD8a2Sirpa+ cDCs, and CD11c+B220+ plasma-
cytoid DCs [12]. Among these three DC subsets, the most
abundant CD8a+Sirpa2 cDCs subset is clustered in the medulla
with a low, but effective AIRE expression, and can present
endogenous self-antigens. Moreover, they can take up self-antigens
from mTECs and cross-present them to the thymocytes [12,13].
However, it still remains elusive on the intrathymic location and
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function of the other minor cDC, CD11c+CD11b+CD8a2Sirpa+
subset. We previously demonstrated that most Sirpa+ cDCs, as
opposed to Sirpa2 cDCs, are disseminated in close proximity to
small vessels in the cortex and inside the perivascular regions [14].
Their unique intrathymic localization allows thymic Sirpa+ cDCs
to selectively capture intravenously injected antigens across the
blood-thymus barrier [14]. Interestingly, mice deficient in a CC
chemokine receptor, CCR2, exhibit a selective decrease in the
Sirpa+ cDC subset in the thymus, with an accumulation of T cells
displaying reactivity against serum self-antigen in the periphery
[14], suggesting the crucial contribution to the central tolerance
against blood-borne antigens.
In the present study, more detailed histological analysis revealed
that thymic Sirpa+ cDCs were disseminated in the cortex and
inside the interlobular vascular-rich regions (IVRs), encompassed
with the cortical parenchyma. Moreover, Sirpa+ cDCs efficiently
captured blood-borne antigen leaking inside the IVRs in a CCR2-
dependent manner. Intravenously injected untreated ovalbumin
(OVA) protein and highly immunogenic heat-aggregated OVA
protein activated thymic Sirpa+ cDCs to initiate antigen-specific
Treg differentiation and negative selection for OVA-specific TCR
transgenic thymocytes, respectively. Moreover, when developed
subcutaneously, tumor induced the deposition of a CCR2 ligand,
CCL2 inside IVRs, resulting in the enhancement of antigen
uptake by intrathymic Sirpa+ cDCs. We finally proved that the
negative selection rather than Treg differentiation ensued in a




Human tissues were obtained from autopsy with a written
informed consent in accordance with the Declaration of Helsinki.
All human studies were approved by the Medical Ethics
Committee of Hokkaido University Graduate School of Medicine.
Thymic tissues were flash-frozen in liquid nitrogen and stored at
280uC.
Plasmids
pMYs-IRES-GFP and pLEGFP-N1 retrovirus vectors were
purchased from Cell Biolabs and Clontech, respectively. An
antagonistic form of CCL2 (7ND) is the amino terminus deleted
form of human CCL2 and can exhibit antagonistic activities
against CCR2 [15]. 7ND-expressing vector was prepared by
cloning to the pMYs-IRES-GFP vector, the human CCL2 NH2-
terminus–deleted cDNA linked with an epitope FLAG tag in the
carboxyl terminal portion [16]. OVA cDNA with a truncated stop
codon was amplified by PCR from chicken OVA cDNA and the
signal peptide sequence of mouse albumin was synthesized as two
complementary oligonucleotides (Gene Design). OVA cDNA
linked with and without albumin signal peptide sequence were
inserted into pLEGFP-N1 vector, to generate sOVA-GFP and
OVA-GFP, respectively.
Transfectants
The Phoenix packaging cell line was transfected with 7ND,
OVA-GFP, or sOVA-GFP retrovirus vector to produce the
retrovirus in the culture supernatant, which was subjected to the
infection. A murine colorectal cancer cell line, Col26 [17] was
infected with the resultant retrovirus to generate clones expressing
stably 7ND, OVA-GFP, or sOVA-GFP. The concentration of
OVA protein in the culture supernatant (16105 cells/ml) was
determined using Chicken Egg Ovalbumin ELISA kit (Alpha
Diagnostic).
Mice
Specific pathogen-free male BALB/c and C57BL/6 mice were
purchased from Charles River Japan, and designated as WT mice.
CCR22/2 mice [18] were kindly provided by Dr. William Kuziel
(University of Texas San Antonio), and were backcrossed to
BALB/c mice for more than 8 generations. CCR22/2 back-
crossed to C57BL/6 mice were provided also by Dr. Kuziel via
Dr. Motohiro Takeya (Kumamoto University). DO11.10 mice
expressing a transgenic TCR that recognizes the OVA323–339
peptide in the context of I-Ad were kindly provided by Dr.
Yasunari Nakamoto (Kanazawa University) and were maintained
as heterozygotes. OT-I and OT-II mice express transgenic TCRs
that recognize the OVA257–264 peptide in the context of H-2K
b
and OVA323–339 peptide in the context of I-A
b, respectively. These
mice were supplied from CARD, Kumamoto University.
DO11.10 mice were mated with CCR22/2 mice to generate
DO11.10/CCR22/2 mice on a BALB/c background. All animal
experiments were approved and performed according to the
Guideline for the Care and Use of Laboratory Animals of
Kanazawa University (permission number AP-111852).
Antibodies (Abs)
The following rat anti-mouse mAbs were used; anti-CD4 (RM4-
5; BD Biosciences), anti-CD8 (53–6.7; BD Biosciences), anti-
CD11b (M1/70; eBioscience), anti-CD25 (PC61; BD Biosciences),
anti-CD172a/Sirpa (P84; BD Biosciences), anti-DC-SIGN (5H10;
eBioscience), anti-DO11.10 clonotypic TCR (KJ1-26; BD Biosci-
ences), anti-Foxp3 (FJK-16s; eBioscience and MF23; BD Biosci-
ences), and anti-Ly-51 (6C3; Biolegend). Mouse anti-mouse I-Ad
(AMS-32.1; BD Biosciences), and hamster anti-mouse CD11c
(HL-3; BD Biosciences), and anti-mouse CCL2 (2H5; eBioscience)
mAbs were used. Rabbit anti-mouse type IV collagen (Col IV)
polyclonal Ab was purchased from LSL. Mouse anti-human
CD172a/Sirpa (15–414; AbD Serotec) and anti-DC-SIGN
(DCN47.5; Miltenyi Biotec) mAbs were used. Isotype-matched
control IgGs for individual mouse, rat, and hamster mAbs were
purchased from BD Biosciences. Rabbit IgG (Sigma-Aldrich)
served as negative controls.
Cell preparation
Thymus and spleen were obtained from 6- to 7-week old mice.
Total thymocytes were isolated by mechanical digestion from
thymus. In some experiments, thymus was digested with 0.6 mg/
ml collagenase type IV (Sigma-Aldrich) and 25 Kunitz units/ml
DNase I (Sigma-Aldrich) at 37uC for 20 min. The resultant single
cell suspensions were further separated by density gradient
centrifugation using Histopaque-1077 reagent (Sigma-Aldrich).
The cells in the interphase were obtained and were used as thymic
low-density cells. Bone marrow cells were flushed out with cold
RPMI 1640 medium (Sigma-Aldrich) from the femoral and tibial
bones.
RT-PCR
Total RNAs were extracted from tissues using a RNeasy Mini
Kit (Qiagen) and then reverse-transcribed using SuperScript III
First-Strand Synthesis System (Invitrogen). PCR was done using
the cDNAs, 2.5 mM dNTP mix (Takara), TaqDNA polymerase
(Takara), and the specific primer sets for GAPDH gene (sense: 59-
CAC TGA GCA TCT CCC TCA CA-39; antisense: 59-TGG
GTG CAG CGA ACT TTA TT-39), DC-SIGN gene (sense: 59-
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CAG TTG AAG GCT GGC GTA G-39; antisense: 59-ACA AGT
TGA GCC CCC ACA T-39), SIGNR1 gene (sense: 59-CAT GCA
GGC GAA GAT CAC T-39; antisense: 59-TAC CGG GAA GCT
GGA GAT C-39), SIGNR2 gene (sense: 59-CTA CTC CCA CGG
ACA AGA ACA-39; antisense: 59-CCA GTT CTG TTG GAA
CTT GGA-39), SIGNR3 gene (sense: 59-GCT GCT TTC CTT
CCT GTT CTT-39; antisense: 59-TCA GCC TTC AGT TGC
ATG AG-39), and SIGNR4 gene (sense: 59-CAG TGG GAA CAC
ACA AAG CA-39; antisense: 59-CAT TTC TTT GCA GGC
AGT CA-39) for 28 cycles (for GAPDH) or 32 cycles (for others) of
95uC for 30 s, 55uC for 30 s, and 72uC for 30 s.
Flow cytometry (FCM)
Total thymocytes and thymic low-density cells were stained with
various combinations of fluorescent dye-conjugated or non-
conjugated specific Abs in magnetic activated cell separation
(MACS) buffer (PBS supplemented with 2 mM EDTA and 3%
FBS). For non-conjugated Abs, fluorescent-conjugated secondary
Abs were used. Intranuclear Foxp3 was stained with the help of
FITC anti-mouse Foxp3 staining set (eBioscience). Expression of
each molecule was analyzed using FACSCalibur or FACSCanto II
(BD Biosciences) with CellQuest Pro software (BD Biosciences)
and FlowJo software (TreeStar).
Immunofluorescence analysis
Six or 15 mm-thick cryostat sections were fixed with cold
acetone for 3 min or with 4% paraformaldehyde for 15 min and
permeabilized with 0.1% Triton X for 15 min, and incubated with
Protein Block Reagent (DAKO) to block non-specific binding.
Then, fluorescent immunostaining was done by the standard
method. After being washed with 0.05% Tween 20-PBS, slides
were mounted in fluorescent mounting medium (VECTOR) with
or without DAPI (DAKO). Immunofluorescence was detected in
the setting that excluded the non-specific signal of the isotype
control, using a fluorescence microscope, BX50 (Olympus), or a
confocal laser scanning microscope, LSM510 (Carl Zeiss). DP
Controller software (Olympus) and Zen 2007 software (Carl Zeiss)
were used for image processing.
Uptake of antigens by thymic DCs
Alexa Fluor 488- (OVA488) or 647-conjugated OVA protein
(OVA647) (Invitrogen) was injected into the tail vein, subcutaneous
region, or peritoneal cavity of mice. FITC-conjugated dextran
(M.W.; 2,000 kDa) (Sigma-Aldrich) was injected into tail vein.
Thymic low-density cells were isolated at 4 hrs after OVA protein
injection and analyzed by FCM. In another experiments, thymi
were subjected to the immunofluorescent staining to observe the
localization of antigen.
In vitro antigen uptake assay
Thymic low-density cells were incubated with 10 mg/ml
OVA647 in RPMI1640 at 37uC for 20 min. Uptake of OVA647
was analyzed by FCM after being stained with anti-CD11c and
anti-Sirpa Abs.
Generation of bone marrow chimeric (BMC) mice
Bone marrow cells were collected from WT and DO11.10 mice.
DO11.10 bone marrow cells were mixed with WT bone marrow
cells at the ratios of 10%, 5%, 2.5%, and 1%. WT mice were
irradiated to 7 Gy by using an x-ray irradiator, RX-650 (Faxitron
X-ray), and were subsequently given 107 mixed bone marrow cells
intravenously.
Effects of OVA antigen on TCR transgenic thymocytes
OT-I, OT-II, and DO11.10 transgenic mice with or without
CCR2 gene deficiency, and BMC mice were administered with
OVA protein (Sigma-Aldrich) or heat-aggregated OVA protein
(80uC for 10 min) in PBS through the tail vein. At the indicated
time points after the treatment, thymocytes were collected and
analyzed by FCM. In some experiments, the thymus was subjected
to immunofluorescence analysis.
In vitro differentiation of Tregs
Thymocytes were isolated from mice 2 days after the last OVA
protein injection and were incubated with 5 ng/ml rIL-7 in the
presence or the absence of the indicated concentrations of rIL-2 in
RPMI1640 supplemented with 10% FCS and 50 mM 2-mercap-
toethanol at 37uC for 24 hrs. In some experiments, cells were pre-
incubated with 2 mg/ml anti-CD25 or anti-CD122 blocking mAbs
and were subsequently stimulated with rIL-2 in the presence of the
same mAbs at 1 mg/ml.
Tumor injection
Five6105 of WT Col26 or their transfectant clones in 200 ml
PBS were injected into the dorsal subcutaneous space of WT,
DO11.10, or DO11.10/CCR22/2 mice.
Statistical analysis
Data were analyzed statistically using one-way ANOVA
followed by the Turkey-Kramer test. Mann-Whitney’s U test or
Kruskal-Wallis test was used in the instances when the data were
not normally distributed. p,0.05 was considered statistically
significant.
Results
Thymic Sirpa+ cDCs are a murine counterpart of human
DC-SIGN+ DCs and can efficiently uptake antigens leaking
inside the IVRs
In WT mouse-derived thymus, thymic Sirpa+ cDCs were
disseminated in the cortex and inside the IVRs, separated by two
Col IV+ basement membranes (Fig. 1A). Consistent with the
report that DC-SIGN+ DCs were present in the cortex and
interlobular regions of human thymus [19,20], we detected DC-
SIGN+ cells in the parenchyma and interlobular region of human
thymus (left panel in Fig. 1B). A double-color immunofluorescence
analysis further revealed that most DC-SIGN+ cells co-expressed
human Sirpa molecule (Fig. 1B). Mouse thymic Sirpa+ cDCs, but
not Sirpa2 cDCs, expressed the transcripts of DC-SIGN,
SIGNR3, and SIGNR4 (Fig. 1C) and DC-SIGN molecule on
their cell surface (Fig. 1D), indicating that mouse thymic Sirpa+
cDCs can be a counterpart of human DC-SIGN+ DCs. When
intravenously injected, FITC-conjugated dextran polysaccharide
leaked through the vessel wall and pervaded inside the IVRs, but
its leakage from small vessels was hardly observed in the
parenchyma (Fig. 1E). Sirpa+ cDCs in the IVRs, but not those
in close proximity to the small vessels in the cortex (upper panel in
Fig. 1F), efficiently captured dextran as revealed by confocal 2-D
and superposed 3-D images (lower panels in Fig. 1F). Intrave-
nously injected OVA protein was also captured mainly by
CD11c+ DC population, especially by those expressing Sirpa
(Fig. 1G). Moreover, thymic Sirpa+ cDCs captured OVA protein,
when it was administered subcutaneously, but not intraperitone-
ally (Fig. 1H). In contrast, CD11b+MHC class IIlowF4/80+ thymic
macrophages failed to take in intravenously injected OVA protein
(Fig. S1).
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Figure 1. Thymic Sirpa+DC-SIGN+ cDCs can uptake antigens, which leak inside the IVRs. (A) Triple-color fluorescent image with the
combination of Col IV (green), Ly-51 (blue), and Sirpa (red) in mouse thymic tissue. Dashed lines indicate the boundary between cortex (C) and
medulla (M). Scale bar, 100 mm. (B) A double-color fluorescent immunostaining for DC-SIGN (green) and Sirpa (red) in human thymic tissue. Dashed
lines indicate the outer margin of thymic lobule. Scale bar, 100 mm. (C) Thymic B2202CD11chighSirpa2 (Sirpa2) and B2202CD11chighSirpa+ (Sirpa+)
cDCs were sorted (Sirpa2 purity, 97.8%; Sirpa+ purity, 97.1%) by using FACSAria (BD Biosciences), from thymic low-density cells isolated from 10 mice.
Expression of DC-SIGN, SIGNR1, SIGNR2, SIGNR3, and SIGNR4 was determined by RT-PCR. GAPDH served as an internal positive control. RT-PCR
analysis was repeated three times. (D) DC-SIGN expression on CD11chighSirpa2 and CD11chighSirpa+ cDCs. Gray-filled and red-open histograms
indicate the results obtained using isotype control and specific mAbs for DC-SIGN, respectively. (E) Thymi were collected at the indicated time points
after FITC-conjugated dextran was intravenously injected into WT mice. Triple-color fluorescent images with the combination of dextran (green), DAPI
(blue), and Col IV (red) are shown here. Scale bar, 200 mm. (F) Triple-color fluorescent images with the combination of dextran (green), Col IV (blue),
and Sirpa (red) at 6 hrs after dextran injection are shown here. The confocal images in the parenchyma nearby small vessel and inside the IVRs, and
superposed 3-D image inside the IVRs are shown in the upper and lower left, and lower right panels, respectively. Scale bars, 50 mm. (G) Uptake of
OVA647 in low density cells at 4 hrs after injection. Percentage of CD11c (+) OVA647 (+) and CD11c (2) OVA647 (+) region are shown. Expression of
Role of Thymic Sirpa+ DCs in Central Tolerance
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Antigen uptake by Sirpa+ cDCs was impaired in CCR2-
deficient thymus
We previously reported that CCR22/2 mouse-derived thymus
preserves the architecture of cortical TECs and mTECs with a
selective decrease in the number of CD11c+CD11b+CD8a2Sirpa+
cDCs [14]. Moreover, CCR2 gene deficiency caused aberrant
localization of Sirpa+ cDCs [14], especially in the IVRs where
Sirpa+ cDCs can efficiently capture antigens, which leaked from
bloodstream (Fig. 1 and illustrated in Fig. 2A). Furthermore, CCR2
gene ablation significantly decreased the proportion of Sirpa+
cDCs capturing OVA protein among total intrathymic CD11chigh
DCs (Fig. 2A). After intravenous OVA protein injection, Sirpa+
cDCs of WT mice contained a substantial proportion of the cells
with a higher uptake of OVA protein, but this population was
markedly decreased by CCR2 gene ablation in both BALB/c and
C57BL/6 mouse strains (Fig. 2B). In contrast, the cells with a
lower OVA protein uptake were present with similar proportions
in both wild-type and CCR22/2 thymus. Moreover, CCR22/2
Sirpa+ cDCs had in vitro a similar level of capacity to capture OVA
protein as WT cells did (Fig. S2). Thus, intrathymic OVA uptake
by Sirpa+ cDCs was impaired in CCR22/2 mouse-derived
thymus, arising from their reduced number and inappropriate
localization in the thymus.
CCR2-deficient thymus is selectively defective in the
tolerogenic roles of Sirpa+ cDCs with reduced
intrathymic Treg differentiation and negative selection
against blood-borne antigens
To examine the function of Sirpa+ cDCs in central tolerance
against blood-borne antigens, OVA protein was intravenously
injected into DO11.10 mice. OVA protein injection induced the
generation of Foxp3+ Tregs in DO11.10high mature thymocytes
(Fig. 2C), which predominantly express a single TCR transgene
[21]. In contrast, an increment of Foxp3+ thymocytes was
markedly attenuated by the absence of CCR2 gene (Fig. 2D). It
was reported that CD25high natural Tregs were spontaneously
differentiated from DO11.10negative to low endogenous TCR-
rearranged thymocytes [21]. However, OVA protein injection
failed to increase Foxp3 expression in this population (Fig. S3).
Likewise, OVA protein injection enhanced the proportion of
Foxp3+ cells in OT-II mice (Fig. S4), but not in OT-I mice of
C57BL/6 background (data not shown). Moreover, IL-17 was also
detected intracellularly in DO11.10negative to low thymocytes
consistent with the previous report [22], but OVA injection failed
to increase DO11.10high thymocytes expressing IL-17 (Fig. S5).
When we injected the heat-aggregated OVA protein, which forms
a highly immunogenic amyloid-like structure [23,24], it markedly
decreased the number of thymocytes in DO11.10 mice, especially
those in CD4+CD8+ (DP) stage, and this reduction was abrogated
in DO11.10/CCR22/2 thymus (Fig. 2E). Given selective
decreases in numbers of Sirpa+ cDCs and their lower capacity
of antigen uptake in the thymus of CCR22/2 mice, thymic Sirpa+
cDCs can essentially contribute to the induction of Treg
differentiation and negative selection, depending on the immuno-
genicity of the presented antigens.
Blood-borne antigen can induce intrathymic Treg
generation in collaboration with IL-2-mediated signal in a
physiological condition
The repeated intravenous injection of OVA protein progres-
sively enhanced Foxp3 expression in CD252DO11.10high thymo-
cytes (Fig. 3A). OVA protein injection alone induced immature
Foxp3+ thymocytes expressing a lower level of CD25 (Fig. 3A), but
mature DO11.10highCD25highFoxp3+ Tregs were consistently
generated by the subsequent in vitro stimulation with IL-2 after
the injection with OVA protein but not PBS (Fig. 3B). The in vitro
stimulation with IL-2 further efficiently increased mature Tregs
following the twice injection of OVA protein, and the increase was
inhibited by anti-CD25 mAb and to a lesser extent, anti-CD122
blocking mAb (Fig. 3C). Moreover, intravenous injection of OVA
protein markedly increased percentage of CD25highFoxp3+ cells
among DO11.10high cell population in BMC mice containing
various percentages of DO11.10 thymocytes to polyclonal
thymocytes, and the increase was correlated inversely with the
chimerism ratios (Fig. 3D). Thus, monoclonal TCR transgenic
thymocytes may compete with each other to receive some
prerequisite signals such as IL-2 from intrathymic environment
during Treg differentiation, as previously reported [25]. Thus,
intrathymic presentation of blood-borne antigens which can be
selectively captured by thymic Sirpa+ cDCs initiates Treg
differentiation in collaboration with some factors such as IL-2.
CCL2-CCR2 axis can enhance the capacity of antigen
uptake by Sirpa+ cDCs in tumor-bearing mice
CCR2 expression by Sirpa+ cDCs prompted us to examine the
function of Sirpa+ cDCs in tumor-bearing mice, because CCR2
ligands, particularly CCL2, are abundantly expressed in tumor-
bearing mice [26]. When murine colorectal cancer cell line, Col26
was subcutaneously injected into WT mice, the proportions of
both DC-SIGN+Sirpa+ and total Sirpa+ cDCs were significantly
increased among thymic CD11chigh cDC population at 14 days
after tumor inoculation (Fig. 4A) and were accumulated in the
IVRs in tumor-bearing mice (Fig. 4B) with a marked increase in
serum CCL2 (Fig. S6B). Immunofluorescence analysis revealed
that CCL2 was intensively detected inside the IVRs in the thymus
derived from tumor-bearing mice (Fig. 4C). The carboxy-terminal
region of chemokines show a high binding affinity for proteogly-
cans on the vascular endothelium and in the extracellular matrix
[27]. Given the abundance of proteoglycans in the IVRs in the
thymus [28], serum CCL2 might be deposited inside the IVRs
through binding with proteoglycan after tumor development. This
assumption is supported by the observation that CCL2 was
detected in the IVRs in non-tumor-bearing mice after intravenous
injection of recombinant (r) CCL2 (Fig. 4C). Furthermore, tumor-
bearing mice exhibited enhanced intrathymic antigen uptake by
Sirpa+ cDCs, but not by Sirpa2 cDCs, when OVA protein was
intravenously injected (Fig. 4D). This enhanced uptake of the
intravenously administered antigen was partially retarded when
OVA protein was intravenously injected into Col26-7ND tumor-
bearing WT mice (Fig. 4E). Col26-7ND produced significantly less
mouse CCL2 than the parental cells in vitro (Fig. S6A). Moreover,
the in vitro co-culture of Col26-7ND reduced mouse CCL2
secretion by the parental cells (Fig. S6A). Thus, 7ND protein can
inhibit endogenous CCL2 production in a paracrine and/or
Sirpa molecule in region 1 (R1) and R2 are represented by unfilled and gray-filled histogram, respectively. (H) Uptake of OVA647 at 4 hrs after
intravenous, subcutaneous, or intraperitoneal injection. Percentage of Sirpa (+) OVA647 (+) region in thymic CD11chigh DCs is shown in each panel.
PBS was injected as a control. Representative results from three independent experiments are shown here.
doi:10.1371/journal.pone.0041154.g001
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autocrine manner. Moreover, WT mice receiving the tumor
expressing 7ND exhibited reduced serum mouse CCL2 concen-
tration compared with WT mice receiving parental Col26 cells
(Fig. S6B). Thus, human 7ND protein could reduce the release of
mouse CCL2 by Col26 cells probably in an autocrine manner.
Compared with wild-type mice, CCR22/2 mice exhibited
depressed uptake of intravenously administered OVA protein
even when they were administered with the parental tumor
Figure 2. Mice deficient in CCR2 gene exhibited reduced Treg differentiation and negative selection in the thymus. (A) Schematic
representation of localization and function of thymic Sirpa+ cDCs. OVA protein uptake by CD11chighSirpa+ cDCs in WT and CCR22/2 thymus at 4 hrs
after injection are shown. Percentage of Sirpa (+) OVA647 (2) and Sirpa (+) OVA647 (+) region are shown in each panel. (B) The uptake of OVA647 by
CD11c+Sirpa+ cDCs derived from C57BL/6 thymi at 4 hrs after injection is shown in left panel. Sirpa+ cDCs capturing OVA647 were separated into two
groups according to the efficiency of OVA647 uptake; low and high. Percentages of cells in low and high regions in WT and CCR2
2/2 mice in BALB/c
and C57BL/6 strain are shown in the right panel. Data represent mean 6 SD from five and three independent experiments in BALB/c and C57BL/6
mice, respectively. (C) Expression of CD25 and Foxp3 on DO11.10high (R1) thymocytes at 2 days after OVA protein injection. Percentage of Foxp3 (+)
region is shown in each panel. Representative results from three independent experiments are shown. (D) The numbers of Foxp3+ mature
thymocytes were determined on DO11.10 and DO11.10/CCR22/2 mice at 2 days after OVA injection. Each symbol represents an individual mouse.
Small horizontal lines indicate the mean. (E) Clonal deletion of thymocytes after OVA injection. Two mg OVA protein or heat-aggregated OVA protein
were intravenously injected into DO11.10 mice. At 2 days after injection, the numbers of total thymocytes (left graph) and DP thymocytes (right
graph) were determined on DO11.10 and DO11.10/CCR22/2 mice. Each symbol represents an individual mouse. **, p,0.01. *, p,0.05. N.S., no
significant difference.
doi:10.1371/journal.pone.0041154.g002
Role of Thymic Sirpa+ DCs in Central Tolerance
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41154
Role of Thymic Sirpa+ DCs in Central Tolerance
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e41154
(Fig. 4E). These observations would implicate the involvement of
the CCL2-CCR2 axis in the uptake of an intravenously
administered antigen by Sirpa+ cDCs. Intravenous injection of
rCCL2 enhanced in vivo the uptake of intravenously injected OVA
protein (Fig. 4E). On the contrary, rCCL2 failed in vitro to enhance
antigen uptake by Sirpa+ cDCs (Fig. S2). Thus, CCL2 deposited
inside the IVRs can induce the trafficking of Sirpa+ cDCs with a
capacity to uptake an intravenously administered antigen into the
IVRs, resulting in central tolerance.
Blood-borne antigen can induce intrathymic negative
selection in tumor-bearing mice
To examine the tolerogenic event induced by blood-borne
antigen, tumor-bearing mice were intravenously injected with
OVA protein. After injection, clonal deletion in OVA-specific
thymocytes, especially at DP stage, obviously occurred in
DO11.10 mice bearing tumor but not in mice without tumor
(Fig. 4F and 4G). This negative selection was partially retarded in
mice bearing Col26-7ND tumor (Fig. 4G). In contrast, Treg
generation was depressed in the mice bearing a parental Col26
tumor (Fig. S7). Thus, tumor development can induce the shift
from Treg differentiation to negative selection, together with
exaggerated antigen uptake by Sirpa+ cDCs.
Tumor-derived secretory antigen can efficiently induce
the intrathymic negative selection
Finally, we examined whether a tumor-derived antigen can
induce the intrathymic Treg differentiation or negative selection.
For this purpose, we established two distinct OVA-GFP fusion
protein-expressing Col26 clones; Col26-OVA and Col26-sOVA
clones, which express the fusion protein only in the cytoplasm and
secrete the fusion protein outside of the cells, respectively. Among
the obtained Col26-sOVA clones, Col26-sOVA clone 4 secreted
OVA-GFP fusion protein into the culture supernatant most
efficiently (Fig. S8A) and was therefore used in the following
experiments. In DO11.10 mice, Col26 cells and Col26-OVA cells
grew at similar rates whereas Col26-sOVA cells grew at slower
rates (Fig. S8B) as previously reported [1,2]. Accordingly, we
obtained thymi at 14 days after Col26 or Col26-OVA injection
and at 22 days after Col26-sOVA injection, because the tumor
sizes were similar at these time points among these three groups.
Compared with DO11.10 mice bearing either Col26 or Col26-
OVA, both DO11.10high mature thymocytes and DO11.10medium
immature thymocytes were decreased in the mice bearing Col26-
sOVA (Fig. 5A and 5B). This negative selection was partially
retarded in DO11.10/CCR22/2 mice at 22 days after Col26-
sOVA injection (Fig. 5A and 5B). In contrast, Treg differentiation
in DO11.10high thymocytes was marginal in mice bearing Col26-
sOVA (Fig. 5C). Thus, a tumor-specific antigen can induce the
intrathymic negative selection but not Treg differentiation, once it
is secreted into bloodstream.
Discussion
Recently, Atibalentja et al reported the involvement of both
Sirpa+ and Sirpa2 cDC in central tolerance to an intravenously
administered hen egg white lysozyme (HEL) [29,30]. Because
molecules with a smaller M.W. than BSA (M.W. 67 kDa) can
diffuse through the blood-thymus barrier and enter the medulla,
HEL (M.W. 14.4 kDa) might be captured by Sirpa2 cDC in
medulla in the previous studies [29,30]. In contrast, we observed
that the Sirpa+ cDCs selectively captured intravenously injected
fluorescent dye-conjugated OVA protein (M.W. 45 kDa) and
presented it to immature thymocytes in the thymic cortical region.
Moreover, thymic Sirpa+ cDCs selectively captured mouse IgG
(150 kDa) [14], heat-aggregated OVA (too large to measure
M.W.) [31], and dextran (M.W. 2,000 kDa), which were injected
intravenously. The adult blood–thymus barrier constitutively
prevents large-sized antigens from permeating into the thymic
parenchyma [32]. However, we observed that dextran with a large
molecular weight permeated inside the IVRs, and was subse-
quently captured efficiently by Sirpa+ cDCs therein. Moreover,
some Sirpa+ cDCs capturing dextran appeared in the thymic
cortical parenchyma at 18 hrs after injection (data not shown).
These observations may mirror our previous observation that
Sirpa+ cDCs captured and conveyed OVA protein into the
cortical parenchyma [14]. Thus, due to its peculiar localization in
the IVR, only Sirpa+ cDCs can directly capture large-sized blood-
borne antigens, which are unable to permeate into thymic
parenchyma.
Thymic Sirpa+ cDCs captured OVA protein, when it was
administered intravenously or subcutaneously, but not intraperi-
toneally. Boelaert J et al. previously reported that serum
concentration of erythropoietin (M.W. 34 kDa) rose more slowly
after subcutaneous injection than after intravenous injection [33].
They further demonstrated that intraperitoneal injection was
much less effective in the raising of serum concentration than
subcutaneous injection. Given the capacity of Sirpa+ cDCs to
capture selectively blood-borne antigens, intraperitonal injection
of OVA protein may not be able to increase its serum
concentration sufficient for Sirpa+ cDCs to capture it in the
thymus.
We demonstrated that thymic Sirpa+ cDCs can capture blood-
borne antigens and can initiate the antigen-specific Treg
differentiation in a physiological condition. The ‘‘two-step model’’
hypothesis proposed that additional IL-2 signal is a prerequisite for
intrathymic Treg differentiation after antigen presentation [34,35].
Consistent with this assumption, we observed that IL-2 induced
Treg precursors to differentiate into mature CD25highFoxp3positive
Tregs without additional TCR engagement. Moreover, the
differentiation of CD25+Foxp3+ mature Tregs was more efficient
in an intraclonal low-competitive condition as revealed by the
experiment using mixed BMC. Thus, Sirpa+ cDCs can capture a
blood-borne antigen and present it to the thymocytes, leading to
Figure 3. Antigen-specific Treg generation by Sirpa+ cDCs in collaboration with IL-2 in a physiological condition. (A) At 2 days after
the last intravenous injection of OVA protein (2 mg) into DO11.10 mice, Foxp3 and CD25 expression on DO11.10high (R1) thymocytes was examined.
PBS was injected as a control. Percentages of CD25highFoxp32, CD25highFoxp3+, and CD25lowFoxp3+ cells are shown in each panel. Representative
results from three independent experiments are shown. (B) Expression of CD25 and Foxp3 on DO11.10high mature thymocytes after stimulation with
IL-2 in vitro. Percentages of CD25highFoxp3+ and CD25lowFoxp3+ cells are shown in each panel. Representative results from three independent
experiments are shown. (C) At 2 days after twice intravenous injection of OVA protein, thymocytes were cultured with 2 ng/ml IL-2 for 24 hrs in the
presence or absence of each blocking Ab. Percentage of CD25highFoxp3+ cells was determined. Data represent mean 6 SD from three independent
experiments. *, p,0.01. (D) Percentage of CD25highFoxp3+ cells among DO11.10high thymocytes in BMC mice was analyzed at 2 days after
intravenous injection with OVA protein. Gray-filled symbol represents OVA protein-injected mice. Data from non-BMC DO11.10 mouse are shown as a
symbol of 100% chimerism of DO11.10 thymocytes. PBS (unfilled circle) and BSA (unfilled triangle) were injected as controls. Percentage of chimerism
=% of DO11.10high thymocytes in BMC thymus/% of DO11.10high thymocytes in non-BMC DO11.10 thymus x 100. Each symbol indicates one animal.
doi:10.1371/journal.pone.0041154.g003
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the efficient generation of Tregs in collaboration with several
factors including IL-2 in a physiological condition.
Accumulation of Sirpa+ cDCs in IVRs can result in more
efficient capture of an intravenously injected antigen and
subsequent intrathymic negative selection. Subcutaneous tumor
formation of Col26 increased the serum concentration of CCL2,
which was deposited in IVRs and attracted Sirpa+ cDCs therein.
Consequently, Sirpa+ cDCs can capture efficiently a secretory
OVA protein and can induce intrathymic negative selection.
However, we cannot exclude the possibility that the secretion of a
tumor-specific antigen may induce the expression of additional
factors, which may induce the intrathymic negative selection in
cooperation with CCR2-expressing Sirpa+ cDCs.
Consistent with the previous reports [1,2], OVA-secreting
tumors grew more slowly in DO11.10 mice than OVA-non-
secreting ones did, in the early phase, despite the absence of in vitro
growth rate difference between OVA-secreting and OVA-non-
secreting cells (data not shown). Thus, when a tumor is
Figure 4. Induction of negative selection by Sirpa+ cDCs in tumor-bearing mice. (A) Thymus was collected at 14 days after Col26 tumor
inoculation. Percentage of DC-SIGN+Sirpa+ and total Sirpa+ cells in thymic CD11chigh DCs in WT mice bearing tumor or mice without tumor are
shown. (B) A double-color fluorescent immunostaining for Sirpa (red) and Col IV (green). Single color image for Sirpa and merged image are shown
on the upper and lower, respectively. Scale bar, 50 mm. (C) A double-color fluorescent immunostaining for Col IV (red) and CCL2 (green). The right
panel shows the thymus which was collected at 1 hr after intravenous injection of rCCL2 (5 mg). Single color image for CCL2 and merged image are
shown on the upper and lower, respectively. Scale bar, 50 mm. (D) Parental Col26 and Col26-7ND were injected into WT mice. Subsequently, OVA647
was intravenously injected at 14 days after tumor inoculation. Uptake of OVA647 in Sirpa
2 (left) and Sirpa+ cDCs (right) were analyzed at 4 hrs after
OVA injection. Parental Col26-, Col26-7ND-bearing mouse, and mouse without tumor were represented by a solid-lined, dash-lined, and gray-filled
histogram, respectively. Representative results from 3 independent experiments are shown here. (E) Enhancement of the capability of OVA uptake by
Sirpa+ cDCs in tumor-bearing mice. Enhancement of OVA uptake = MFI of OVA647 captured by Sirpa
+ DCs in WT or CCR22/2 mice bearing parental
Col26 or Col26-7ND tumor/that in WT or CCR22/2 mice without tumor. The right unfilled column shows the fold-enhancement of OVA647, when
OVA647 was injected at 1 day after three times of daily injections of rCCL2 (2.5 mg/injection). (F) Two mg OVA protein was intravenously injected into
DO11.10 mice at 14 days after tumor inoculation and 2 days later, expression of CD4 and CD8 in DO11.10+ thymocytes was analyzed. Percentage of
DP thymocytes is shown in each panel. Data represent mean6 SD from three independent experiments. (G) The numbers of total thymocytes (upper
graph) and DP thymocytes (lower graph) are shown. Representative results from three (B and C) or four (D and F) independent experiments are
shown here. Data represent mean 6 SD from four independent experiments (A, E, and G). *, p,0.01.
doi:10.1371/journal.pone.0041154.g004
Role of Thymic Sirpa+ DCs in Central Tolerance
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e41154
impalpable, a secretory OVA protein may induce intratumoral
expansion of DO10.11 T lymphocytes, which can exhibit immune
surveillance against an OVA-expressing tumor. In contrast, when
a tumor becomes palpable, OVA protein may circulate system-
ically to reach thymus. Thymic Sirpa+ cDCs can uptake OVA
protein and subsequently induce intrathymic negative selection in
DO11.10 mice. Thus, if thymic Sirpa+ cDCs can be well tuned,
the secretory tumor-specific antigens may become more beneficial
for the immune surveillance against a tumor.
Herein, we have unraveled a pivotal role for thymic Sirpa+ cDC
subset in the distinct surveillance against blood-borne antigens in
the central tolerance system. Moreover, we proved that an
inflammatory chemokine receptor, CCR2, have profound effects
on the tolerogenic capacity of thymic Sirpa+ cDCs. We recently
demonstrated that ablation of the CCR2 gene exacerbated the
pathology of polyarthritis spontaneously developed in IL-1
receptor antagonist-deficient mice [36], suggesting its immune
regulatory roles in autoimmunity. Moreover, mouse thymic Sirpa+
cDCs can be a counterpart of human thymic DC-SIGN+Sirpa+
DCs, the cells that are presumed to be involved in thymocyte
selection in humans [19,20]. Thus, in both mice and humans, this
cell population may regulate immune responses against blood-
borne antigens and eventually have pathophysiological roles in the
various disorders representing abnormal immune status, including
cancer, autoimmune diseases, and allergy.
Supporting Information
Figure S1 Uptake of blood-borne antigen by thymic
CD11b+ DCs, but not macrophages. CD11b+MHC class II+
DCs (R1) and F4/80+ macrophages (R3) among CD11b+MHC
class II2 cells (R2) were gated to analyze the uptake of OVA488
(red line-histogram). Autofluorescence of each population is
represented by gray-filled histogram. Representative results from
two independent experiments are shown here.
(TIF)
Figure S2 In vitro antigen uptake by thymic Sirpa+
cDCs. In vitro uptake of OVA647 by thymic Sirpa
+ cDCs which
were isolated from WT, CCR22/2, or WT mice after three times
of daily injections of rCCL2 (2.5 mg/injection) was examined. MFI
of OVA647 captured by CD11c
highSirpa+ cDCs was determined
and mean 6 SD from three independent experiments was shown.
(TIF)
Figure S3 Natural DO11.10negative to low Tregs. At 2 days
after DO11.10 mice received intravenous injection of OVA
protein (2 mg), CD25 and Foxp3 expression on DO11.10negative to
low (R1) thymocytes was examined. PBS was injected as a control.
The proportion of CD25highFoxp3+ and CD25lowFoxp3+ cells is
shown in each panel. Representative results from three indepen-
dent experiments are shown here.
(TIF)
Figure S4 Induction of Treg differentiation in C57BL/6
background. At 2 days after intravenous injection of OVA
protein (2 mg) into OT-II mice, expression of CD25 and Foxp3 on
Va2 TCRhigh thymocytes was analyzed. PBS was injected as a
control. Percentage of Foxp3 (+) region is shown in each panel.
Representative results from three independent experiments are
shown here.
(TIF)
Figure 5. Tumor-derived secretory antigen can efficiently induce the intrathymic negative selection. (A) At 14 days after inoculation of
parental Col26 and Col26-OVA, or at 22 days after inoculation of Col26-sOVA, each developmental stage of thymocytes was determined on DO11.10
or DO11.10/CCR22/2 mice. Expression of DO11.10 TCR on total thymocytes is shown. (B) The numbers of DO11.10medium immature thymocytes (left
graph) and DO11.10high mature thymocytes (right graph) were determined on DO11.10 or DO11.10/CCR22/2 mice bearing each tumor. Data
represent mean 6 SD from three independent experiments. *, p,0.01. (C) Intrathymic Treg differentiation in the tumor-bearing mice. Percentage of
DO11.10highFoxp3+ Tregs is shown in each panel. Representative results from three (A and C) independent experiments are shown here.
doi:10.1371/journal.pone.0041154.g005
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Figure S5 Intrathymic Th17 differentiation. At 2 days
after twice intravenous injection of OVA protein (2 mg), total
thymocytes were stimulated with PMA (50 ng/ml) and ionomycin
(1 mg/ml) in the presence of GolgiStop Protein Transport
Inhibitor (BD Biosciences) for 6 hrs. Expression of IL-17 and
Foxp3 were analyzed by FCM, using Mouse Th17/Treg
Phenotyping Kit (BD Biosciences). Percentage of IL-17 (+) Foxp3
(2), IL-17 (+) Foxp3 (+), and IL-17 (2) Foxp3 (+) region are shown
in each panel. Representative results from three independent
experiments are shown here.
(TIF)
Figure S6 Human 7ND protein reduces the release of
mouse CCL2 by Col26 cells in an autocrine manner. (A)
Either parental Col26 or Col26-7ND (16105) or the mixture of
these cells (26105) at a ratio of 1 to 1 was suspended in 1 ml of
culture medium. Culture supernatants were collected 2 days after
the incubation and concentration of mouse CCL2 in the
supernatant was determined by using mouse CCL2/JE/MCP-1
immunoassay kit (R&D Systems), which do not show cross-
reactivity against human CCL2. (B) Parental Col26 or Col26-7ND
cells were injected into WT mice. Subsequently, serum concen-
tration of mouse CCL2 was determined at 14 days after tumor
inoculation. Serum CCL2 was not detected (N.D.) in mice without
tumor. Data represent mean 6 SD from three independent
experiments. *, p,0.05. **, p,0.01.
(TIF)
Figure S7 Defect in intrathymic Treg generation in
mice bearing tumor. Two mg OVA protein was intravenously
injected into DO11.10 mice at 14 days after tumor inoculation. At
2 days after the injection, the number of DO11.10highFoxp3+
Tregs was determined. Data represent mean 6 SD from three
independent experiments. *, p,0.01.
(TIF)
Figure S8 Growth of Col26 secreting OVA protein was
retarded in DO11.10 mice. (A) Col26-OVA and 4 clones of
Col26-sOVA were established. Culture supernatant was collected
after the incubation of 16105 cells in 1 ml for 2 days.
Concentration of OVA protein in the supernatant was deter-
mined. (B) Tumor size was measured at every two days after
subcutaneous injection of 56105 cells into DO11.10 mice. The
growth of parental Col26, Col26-OVA, and Col26-sOVA cells
were represented by unfilled, gray-filled, and black-filled symbols,
respectively. Tumor volume (mm3) = Length x Width x Depth/2.
Data represent mean 6 SD from three independent experiments.
(TIF)
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